Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
IgG Monoclonal Gammopathy of Uncertain Significance clinical trials
1 of 1 indexed IgG Monoclonal Gammopathy of Uncertain Significance trials are currently recruiting.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
IgG Monoclonal Gammopathy of Uncertain Significance: 1 US clinical trial tracked, 1 recruiting.
IgG Monoclonal Gammopathy of Uncertain Significance is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is Dana-Farber Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition igg-monoclonal-gammopathy-of-uncertain-significance
OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
IgG Monoclonal Gammopathy of Uncertain Significance lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for IgG Monoclonal Gammopathy of Uncertain Significance on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
IgG Monoclonal Gammopathy of Uncertain Significance is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
Phase data not available
Top Sponsors
US sites by state
Facility locations filed on IgG Monoclonal Gammopathy of Uncertain Significance trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this IgG Monoclonal Gammopathy of Uncertain Significance page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 IgG Monoclonal Gammopathy of Uncertain Significance trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Dana-Farber Cancer Institute sponsors the most IgG Monoclonal Gammopathy of Uncertain Significance trials on record, review their full trial history before evaluating a specific study. See Dana-Farber Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This IgG Monoclonal Gammopathy of Uncertain Significance condition card totals 1 registered trials; top US site state New Hampshire. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.